Home › Trials › NCT06541652

Observational study of rare primary liver cancers in France

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Observational Federation Francophone de Cancerologie Digestive · NCT06541652

This study looks at rare types of liver cancer in France to see how they behave and how well different treatments work for patients.

Quick facts

Study typeObservational
Enrollment150 (estimated)
Ages18 Years and up
SexAll
SponsorFederation Francophone de Cancerologie Digestive Academic / other
Locations40 sites (Amiens and 39 other locations)
Trial IDNCT06541652 on ClinicalTrials.gov

What this trial studies

This multicenter observational study aims to describe the clinical, histological, and radiological features of rare primary liver cancers, including hepatocholangiocarcinoma and fibrolamellar carcinoma. It will collect biological tumor samples and blood to evaluate the efficacy of treatments received in clinical practice, helping to determine optimal therapeutic sequences. The findings will serve as a foundation for future translational studies aimed at identifying new biomarkers for diagnosis and treatment evaluation.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed rare primary liver cancers diagnosed after January 1, 2018.

Not a fit: Patients without access to a tumor block or lacking social security may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and treatment strategies for patients with rare primary liver cancers.

How similar studies have performed: While this study focuses on rare cancers, similar observational studies have shown success in identifying treatment patterns and biomarkers in other cancer types.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* 18 years of age or older,
* with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
* diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
* for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.

Exclusion Criteria:

* without social security
* No access to tumor block

Where this trial is running

Amiens and 39 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions HepatocholangiocarcinomaFibrolamellar CarcinomaHepatic Epithelioid HemangioendotheliomaHepatoblastomaHepatic Neuroendocrine CarcinomaHepatic CarcinosarcomasHepatic CystadenomaHepatic Leiomyosarcomas
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.